---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-016984"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2022-03-31T23:59:59+00:00"
generated_at: "2026-06-26T12:32:54.009246+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Helix Acquisition shareholders approve business combination with MoonLake, name change to MoonLake Immunotherapeutics

## Summary
- Business Combination Agreement with MoonLake Immunotherapeutics AG approved; 11.5M votes for, 549K against.
- Name change to "MoonLake Immunotherapeutics" and adoption of amended charter authorized.
- Shareholders redeemed 8,080,845 Class A shares at ~$10.00/share for aggregate ~$80.8M cash.
- Incentive Plan (MoonLake Immunotherapeutics 2022 Equity Incentive Plan) approved with 12.0M votes for.
- Issuance of shares to BVF shareholders and ML Parties approved under Nasdaq listing rules.

## SEC filing metadata
- accession: 0001213900-22-016984
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2022-03-31T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000121390022016984/0001213900-22-016984-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000121390022016984/ea157748-8k_helixacq.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-016984
- JSON: https://secwatch.observer/filing/0001213900-22-016984.json
- Plain text: https://secwatch.observer/filing/0001213900-22-016984.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.